Calyx’s industry-leading RIM (Regulatory Information Management) system has reportedly been selected by the world’s top 10 pharma companies for critical submissions of clinical development data to global regulators through 2026.

The five-year contract signed by the top 10 companies with Calyx demonstrates the continued use of RIM, ensuring fulfillment of regulatory requirements worldwide.

In this context, John Blakeley, Chief Commercial Officer at Calyx, expressed that they value the faith the global pharmaceutical firms have put in them and are thrilled to continue their relationship while providing breakthrough medical treatments and vaccines to people across the globe.

Calyx’s selection can be credited to the companies’ long history with the Calyx RIM solution and the confidence that the firm will continue to support submissions across the company's broad worldwide portfolio.

Calyx RIM, developed by Calyx in-house regulatory professionals, is a tested, proven, robust technology that streamlines and improves the regulatory submission process, and is constantly updated to match worldwide health authorities' rising submission standards.

Calyx RIM publication module allows pharmaceutical businesses to build and submit comprehensive dossiers to worldwide regulatory agencies.

The company’s relationship with Microsoft, and its usage of new cloud-based technologies that keep customers ahead of developing regulatory standards, further adds to the RIM system's value. Calyx RIM on Microsoft Azure delivers system upgrades targeted to customers' needs and schedules, guaranteeing minimal downtime and continued compliance with global regulatory requirements.

Calyx, with its proficiency in clinical development and over 25 years of experience in aiding trial sponsors and clinical research institutions to solve complexities, offers timely insights and brings innovative medications to the industry through innovative eClinical and Regulatory solutions and services. The company has supported over 60,000 trials, 75+ breakthrough therapy approvals, and over 18 million patients to date.

Source Credit-

https://www.prnewswire.com/news-releases/calyx-rim-selected-by-top-10-global-pharmaceutical-company-for-five-year-agreement-301407042.html